PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Paclitaxel
Related studies linked through entity extraction aliases.
Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
- Status
- RECRUITING
- Phase
- PHASE2
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE3
Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)
- Status
- RECRUITING
- Phase
- PHASE3
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC
- Status
- RECRUITING
- Phase
- PHASE1
JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC
- Status
- RECRUITING
- Phase
- PHASE2
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Status
- RECRUITING
- Phase
- PHASE3
A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)
- Status
- TERMINATED
- Phase
- PHASE2
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
- Status
- RECRUITING
- Phase
- PHASE1
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
AK129 Combination Therapy for Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3